| __timestamp | Neurocrine Biosciences, Inc. | Viking Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 17986000 | 1244910 |
| Thursday, January 1, 2015 | 32480000 | 5029636 |
| Friday, January 1, 2016 | 68081000 | 4846776 |
| Sunday, January 1, 2017 | 169906000 | 5329003 |
| Monday, January 1, 2018 | 248932000 | 7121000 |
| Tuesday, January 1, 2019 | 354100000 | 9128000 |
| Wednesday, January 1, 2020 | 433300000 | 10731000 |
| Friday, January 1, 2021 | 583300000 | 10701000 |
| Saturday, January 1, 2022 | 752700000 | 16121000 |
| Sunday, January 1, 2023 | 887600000 | 37021000 |
| Monday, January 1, 2024 | 1007200000 |
Data in motion
In the competitive landscape of biotechnology, effective cost management is crucial. Over the past decade, Neurocrine Biosciences, Inc. and Viking Therapeutics, Inc. have demonstrated contrasting trajectories in their Selling, General, and Administrative (SG&A) expenses. Neurocrine Biosciences has seen a staggering 4,800% increase in SG&A expenses from 2014 to 2023, reflecting its aggressive growth and expansion strategies. In contrast, Viking Therapeutics, while also experiencing growth, has maintained a more conservative increase of approximately 2,900% over the same period. This divergence highlights the varied strategic approaches within the biotech sector. As of 2023, Neurocrine's SG&A expenses are nearly 24 times higher than those of Viking, underscoring its larger operational scale. These insights provide a window into how these companies allocate resources to support their business objectives, offering valuable lessons for investors and industry stakeholders alike.
Comparing SG&A Expenses: Bristol-Myers Squibb Company vs Viking Therapeutics, Inc. Trends and Insights
Comparing SG&A Expenses: Takeda Pharmaceutical Company Limited vs Neurocrine Biosciences, Inc. Trends and Insights
Neurocrine Biosciences, Inc. vs Sarepta Therapeutics, Inc.: SG&A Expense Trends
Neurocrine Biosciences, Inc. and Opthea Limited: SG&A Spending Patterns Compared
Neurocrine Biosciences, Inc. or Perrigo Company plc: Who Manages SG&A Costs Better?
Comparing SG&A Expenses: Neurocrine Biosciences, Inc. vs MorphoSys AG Trends and Insights
Neurocrine Biosciences, Inc. and Vericel Corporation: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Neurocrine Biosciences, Inc. vs Protagonist Therapeutics, Inc. Trends and Insights
SG&A Efficiency Analysis: Comparing Ascendis Pharma A/S and Viking Therapeutics, Inc.
Who Optimizes SG&A Costs Better? Viking Therapeutics, Inc. or Xenon Pharmaceuticals Inc.
Viking Therapeutics, Inc. vs Bausch Health Companies Inc.: SG&A Expense Trends
SG&A Efficiency Analysis: Comparing Viking Therapeutics, Inc. and Wave Life Sciences Ltd.